Very proud to present the ARNEO study published in @EUplatinum!!
In high-risk PCa patients, neoadjuvant degarelix plus apalutamide prior to RP results in significantly improved pathological response compared to degarelix alone!
@joniau
A thread🧵👇:
https://t.co/6JG17AiV5u
@jryckman3@ASTRO_org@urotoday ADT in both arms was deliberate: isolates apalutamide's contribution AND enables the pathological co-primary endpoint (pCR/MRD) — impossible in a surgery-alone design. Deep pathological response predicts BCR-FS and MFS. A scientific necessity, not a flaw. @devos_gaetan@TheGiesen
Pleased to share that our editorial has been published in European Urology Oncology. We reviewed the randomized evidence on metformin in prostate cancer and found no consistent improvement in meaningful oncologic outcomes across disease stages. The recent SAKK 08/14 trial highlights how future progress may depend less on empirical drug repurposing and more on biomarker-driven strategies, with PTEN as a potential lead. @devos_gaetan@EurUrolOncol
https://t.co/uiWWWoprMz
ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer by Gaëtan Devos et al
Full article: https://t.co/SEksVXocqP
Congratulations again to #ARNEO study @devos_gaetan@joniau@TheGiesen
▶️MRD doesn't predict BCR
▶️We will need to wait for a possible significant impact on MFS with longer FU
▶️ypT stage correlates with outcomes
👉 Did downstaging after neoadjuvant treatment correlate with BCR?
Today we presented the 3 year oncological outcomes of the ARNEO trial:
- Patients treated with 3 mo neoadjuvant ADT + Apalutamide have tendency towards improved BCR free and metastasis free survival.
- pT2 disease associated with less biochemical recurrence.
@joniau@TheGiesen
Three-year oncological outcomes of the randomized phase II trial #ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for HR #ProstateCancer. Presented by @devos_gaetan@UZLeuven. #EAU24 written coverage > https://t.co/vEATSLrM7G @RKSayyid
Één van mijn mentoren @joniau
Erg toffe mens, uitstekende wetenschapper en dito chirurg.
Veel van geleerd en nog veel van aan het leren 🙂
https://t.co/mwTBOTibPK
Nice work by @KarelDavid_ !
Three months of neoadjuvant ADT in high-risk PCa patients results in early bone loss. These findings underscore the importance for bone health prevention in men treated with ADT . @Uroweb@UZLeuven
Great presentation of #ARNEO results by @joniau#UroOnco23 Neoadjuvant treatment apa/ADT vs ADT prior to RP in #prostatecancer: BCR not sign. different yet + MRD does not seem to be a good surrogate for BCR. But: downstaging to pT2 was higher with apa/ADT + correlated with BCR
Excellent PhD defense by Gaetan Devos. New treatment options in high-risk prostate cancer and a new proof of the power of metastatis-directed therapy in oligometastatic prostate cancer. Proud to be copromotor 🙏 #respect#prostate#cancer#SBRT#oligo @joniau
Great achievement by @devos_gaetan and the entire @joniau led @KU_Leuven group, this paper in @EUplatinum
Looking forward to the follow-up projects 💥
https://t.co/RGroTNGGiQ